PD-1 expression and clinical PD-1 blockade in B-cell lymphomas

Zijun Y. Xu‐Monette(Duke University), Ken H. Young(Duke Medical Center)

Blood

November 8, 2017

10.1182/blood-2017-07-740993

Cited by 429

Related Papers

Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

|Journal of Clinical Oncology|2012|682

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|677

Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant–Associated Anaplastic Large-Cell Lymphoma

|Journal of Clinical Oncology|2015|418

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2012|390

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2013|246